Safety, tolerability and pharmacodynamics of a novel immunomodulator, MIS416, in patients with chronic progressive multiple sclerosis

BACKGROUND: Preclinical studies have demonstrated that MIS416, a bacterially derived immune modulator, targets myeloid cells following systemic delivery. MIS416 stimulated myeloid cells have the capacity to regulate innate inflammation, a potential therapeutic target for progressive multiple scleros...

Descripción completa

Detalles Bibliográficos
Autores principales: Luckey, Alison M, Anderson, Tim, Silverman, Michael H, Webster, Gill
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2015
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5433401/
https://www.ncbi.nlm.nih.gov/pubmed/28607691
http://dx.doi.org/10.1177/2055217315583385

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5433401/
https://www.ncbi.nlm.nih.gov/pubmed/28607691
http://dx.doi.org/10.1177/2055217315583385

Ejemplares similares